Gaudium IVF and Women Health Ltd (GAUDIUMIVF) is currently trading at 106.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Gaudium IVF and Women Health Limited operates an IVF-focused fertility and women’s healthcare platform using a hub-and-spoke model across nine Indian states, supported by IVF, ICSI, IUI, fertility preservation, reproductive surgeries, counselling, pharmacy, and related hospital services. Its network comprises nine hubs, 38 spokes, and three international spokes in Sydney, Nigeria, and Paris. The company combines clinical operations with proprietary or integrated AI tools, SiD and ERICA, covering sperm selection and embryo assessment. It reports a 62% first-attempt success rate, 85% success across multiple attempts, and an early 8–9% improvement associated with these tools, although the presentation does not provide independent validation or detailed methodology. Gaudium IVF is pursuing aggressive physical expansion shortly after its 2026 BSE and NSE listing. South Delhi and Gurgaon hubs have been inaugurated, Nagpur is awaiting licence approval, and management targets seven more hubs in FY27, eight new centres in FY28, and one in FY29, creating substantial execution and ramp-up requirements. Consolidated Q2 FY27 revenue grew 17.9% year-on-year to ₹37.41 crore, but EBITDA declined 2.1% and PAT was broadly flat at ₹9.41 crore. H1 revenue increased 14.7%, while EBITDA and PAT fell 16.1% and 10.5%, respectively, reflecting marketing expenditure and fixed costs from newly launched hubs. The business has a notable international and medical-tourism proposition, serving patients from more than 30 countries and highlighting India’s lower treatment costs. However, revenue remains concentrated in IVF treatment at 73.06%, with pharmacy contributing 25%, making clinical outcomes, patient acquisition efficiency, and successful centre maturation central to future performance.

Over the past 52 weeks, Gaudium IVF and Women Health Ltd has traded between a low of ₹69.50 and a high of ₹163.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Gaudium IVF and Women Health Ltd has a market capitalization of approximately 771.18. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Gaudium IVF and Women Health Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 33.27 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 771.18 Cr, Gaudium IVF and Women Health Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Gaudium IVF and Women Health Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Gaudium IVF and Women Health Ltd is 33.27. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Gaudium IVF attributed the decline to marketing spending and high fixed costs at new hubs that were still in early ramp-up. Consolidated H1 FY27 PAT was Rs 11.19 crore, down from Rs 12.51 crore in H1 FY26, despite a rise in revenue.

Gaudium IVF had Rs 39.8804 crore unutilised at September 30, 2026. This amount included Rs 39.3489 crore of unused fresh proceeds and Rs 53.15 lakh of net interest earned on fixed deposits after taxes.

Gaudium IVF reported consolidated revenue from operations of ₹37.41 crore for the quarter ended September 30, 2026. This compared with ₹19.38 crore in the June 2026 quarter and ₹31.73 crore in the September 2025 quarter.

Gaudium IVF identifies six replacement cities in its proposed variation but does not explain the reasons for each substitution. The revised cities are Vijayawada, Nashik, Bhubaneswar, Dhanbad, Varanasi and Gorakhpur.